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Introduction {#cam4864-sec-0001}
============

Advanced or metastatic prostate cancer is initially amenable to androgen deprivation therapy (ADT), but eventually escapes from the therapeutic pressures and evolves into castration‐resistant prostate cancer (CRPC) [1](#cam4864-bib-0001){ref-type="ref"}. The molecular mechanisms of adaptive resistance to ADT have been extensively studied to identify new therapeutic options [2](#cam4864-bib-0002){ref-type="ref"}, [3](#cam4864-bib-0003){ref-type="ref"}. Various therapeutic agents against CRPC were approved [4](#cam4864-bib-0004){ref-type="ref"}, [5](#cam4864-bib-0005){ref-type="ref"} or currently under evaluation in clinical trials [6](#cam4864-bib-0006){ref-type="ref"}. However, there are still no effective therapeutic regimens available for CRPC. Therefore, the targetable molecules and pathways for biological vulnerability of CRPC are needed to be identified to develop novel promising therapeutic modalities.

Geraniol is an acyclic monoterpene alcohol that is found in essential oils of fruits and herbs [7](#cam4864-bib-0007){ref-type="ref"}. Geraniol has been shown to exert a chemotherapeutic activity against various types of cancer, such as pancreas and colon cancer [8](#cam4864-bib-0008){ref-type="ref"}, [9](#cam4864-bib-0009){ref-type="ref"}, [10](#cam4864-bib-0010){ref-type="ref"}. We have found that geraniol specifically suppresses the growth of prostate cancer in cultured cell and xenograft tumor models [11](#cam4864-bib-0011){ref-type="ref"}, [12](#cam4864-bib-0012){ref-type="ref"}, compared to linalool, another structurally similar monoterpene that induce no apparent phenotype changes [12](#cam4864-bib-0012){ref-type="ref"}, [13](#cam4864-bib-0013){ref-type="ref"}. These results suggest that geraniol can be exploited as chemical moiety for developing anticancer drugs or as a valuable chemical probe for dissecting complex biological processes, discovering hidden molecular relations, and identifying therapeutic target molecules and pathways. However, the molecular mechanisms by which geraniol induces the changes in cellular phenotypes have been little investigated, particularly at the genome‐wide level.

In this study, we performed DNA microarray experiments to explore the molecular mechanisms of antitumor action of geraniol in prostate cancer cells. Through computational analyses, we identified that E2F8 is a target transcription factor of geraniol and the knockdown of E2F8 suppresses cell growth. In addition, we found that E2F8 is associated with poor survival of prostate cancer patients. Our findings provide insight into understanding the antitumor actions of geraniol, unraveling the role of E2F8 in CRPC biology, and developing novel therapeutic strategies.

Materials and Methods {#cam4864-sec-0002}
=====================

Cell culture and microarray {#cam4864-sec-0003}
---------------------------

PC‐3 prostate cancer cells were treated with 1 mmol/L geraniol or linalool in 0.1% ethanol (vehicle) for 24 h and then DNA microarray experiments were performed as described in our previous study [14](#cam4864-bib-0014){ref-type="ref"}. The microarray data are available through the Gene Expression Omnibus (GEO) database (accession number [GSE45567](GSE45567)). Rigorous data preprocessing for quality control and normalization were performed as described in our previous study [15](#cam4864-bib-0015){ref-type="ref"}. The combined microarray data set contained 11,877 genes which were mapped from microarray probes using a custom mapping file from the BrainArray resource (version 14.0.0) (<http://brainarray.mbni.med.umich.edu/brainarray/>). The normalized data of 121 microarray samples were used for constructing PC‐3 cell‐specific interactome, which is available from GEO (GSE67157).

Unsupervised clustering analysis, internal cluster validation, and supervised classification {#cam4864-sec-0004}
--------------------------------------------------------------------------------------------

For the transcriptional subtyping of the microarray data, we performed unbiased clustering analysis in a uniform manner. We used an unsupervised feature selection method to determine 5000 genes of high variance across all microarray samples [16](#cam4864-bib-0016){ref-type="ref"} and then performed clValid on the data of 5000 genes to measure an optimized clustering size using different clustering algorithms such as, Clustering LARge Applications (CLARA), hierarchical, k‐means [17](#cam4864-bib-0017){ref-type="ref"}, and Partitioning Around Medoids (PAM) [18](#cam4864-bib-0018){ref-type="ref"}. In clValid test, Dunn index for every cluster size each clustering algorithm was obtained to assess both intracluster homogeneity and intercluster separation by the ratio of the smallest distance between observations not in the same cluster to the largest intracluster distance [19](#cam4864-bib-0019){ref-type="ref"}. The clusters were validated through principal component analysis (PCA). The first and second principal components in the PCA plot were used to calculate the sum of % variances, and average (*λ*) and standard deviation (*σ*) of the Euclidean distance (ED) between a medoid and a sample in each cluster. For supervised classification, Random Forest, which is an ensemble learning method for classification and regression, was used to validate the clusters [20](#cam4864-bib-0020){ref-type="ref"}.

SAM and GSEA {#cam4864-sec-0005}
------------

Significance analysis of microarrays (SAM) analysis was used to identify differentially expressed genes (DEGs) out of the 5000 genes among the clusters. A tuning parameter, delta of 0.4, optimized the cutoff for significance with the estimation of false discovery rate (FDR) threshold *q*‐value of 0.01. GSEA (gene set enrichment analysis) using geraniol‐specific DEGs was performed to obtain biological interpretation of gene signatures, and visualized mutually enriched gene signatures using EnrichmentMap [21](#cam4864-bib-0021){ref-type="ref"}.

Prostate cancer‐specific interaction network and MRA {#cam4864-sec-0006}
----------------------------------------------------

ARACNe algorithm [22](#cam4864-bib-0022){ref-type="ref"} was used to reconstruct prostate cancer‐specific transcriptional interactome as previously described [15](#cam4864-bib-0015){ref-type="ref"} with a few modifications. The 5000 genes of high variance in the microarray data and transcription factors (TFs) were used to infer the direct interactions among TFs and their regulons. We updated the list of human TFs from Animal Transcription Factor Database (AnimalTFDB) [23](#cam4864-bib-0023){ref-type="ref"} and transcriptional regulatory gene signatures of Gene Ontology (GO), which are registered in MsigDB 4.0 [24](#cam4864-bib-0024){ref-type="ref"}, such as REGULATION_OF_TRANSCRIPTION (GO:0045449) and TRANSCRIPTION_FACTOR_ACTIVITY (GO: 0003700). MRA‐Fisher\'s exact test (FET) [25](#cam4864-bib-0025){ref-type="ref"} and MAster Regulator INference algorithm (MARINa) [26](#cam4864-bib-0026){ref-type="ref"} were used to infer master regulator candidates and their targets in prostate cancer interactome. The ARACNe preprocessing and MRA‐FET analysis were run in geWorkbench software. MARINa results were visualized by geWorkbench version 2.6.0 (<http://www.geworkbench.org>) [27](#cam4864-bib-0027){ref-type="ref"}.

Biomedical data analysis {#cam4864-sec-0007}
------------------------

We analyzed the microarray data sets of prostate cancer patients, GSE21034 [28](#cam4864-bib-0028){ref-type="ref"} and GSE3325 [29](#cam4864-bib-0029){ref-type="ref"}, to examine E2F8 expression levels in different prostate cancer stages using ANOVA test. After normalization as described in our previous study [14](#cam4864-bib-0014){ref-type="ref"}, Affymetrix probe sets were mapped to Entrez Gene IDs using custom mapping files from the BrainArray resource (version 17.1.0). Then, the data sets of GSE21034 and GSE3325 were combined by overlapping genes and went through batch adjusting. Statistical analysis and data processing were performed using R (version 3.1.2) (<https://www.r-project.org/>) [30](#cam4864-bib-0030){ref-type="ref"}. The nonparametric Kaplan--Meier method was employed to obtain survival curves and the log‐rank test was used to determine overall survival from the International Cancer Genome Consortium (ICGC) dataset as previously described [31](#cam4864-bib-0031){ref-type="ref"}. For these analyses, *P = *0.05 was considered significant.

Lab experiments {#cam4864-sec-0008}
---------------

RT‐PCRs were performed using specific primers for E2F8 and *β*‐actin [32](#cam4864-bib-0032){ref-type="ref"}, [33](#cam4864-bib-0033){ref-type="ref"}. Antibody against E2F8 was obtained from Bethyl laboratories (Montgomery, TX). Antibodies to pCdk2^Y15^, pHistone H3^S10^, Cdk2, and Histone H3 were purchased from Abcam (Cambridge, UK). Anti‐tubulin antibody was supplied by Sigma‐Aldrich (St. Louis, MO). The cell extracts were resolved on 6--13.5% SDS‐PAGE gels and were probed with the indicated antibodies. Cell cycle and growth was assessed by propidium iodide staining and 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assays [15](#cam4864-bib-0015){ref-type="ref"}. Mitotic block experiments were performed as previously described [34](#cam4864-bib-0034){ref-type="ref"}. Cells were synchronized by arresting them at G~1~/S phase with 2 mmol/L thymidine 18 h, followed by a 4 h release, and then cells were arrested at G~2~/M phase with 100 ng/mL nocodazole for 16 h. Geraniol was treated at the same time as nocodazole. The cells were released from nocodazole block by washing with fresh medium. For a rescue experiment, PC‐3 cells were transfected with human E2F8 in pcDNA3 plus pEGFP and then incubated with 1 mmol/L geraniol for 24 h prior to flow cytometric analysis or western blotting.

Statistical analysis {#cam4864-sec-0009}
--------------------

The comparison of the means among experimental groups was performed using one‐way ANOVA (Bonferroni\'s multiple comparison test) followed by a post hoc test. For these analyses, *P *= 0.05 was considered significant.

Results {#cam4864-sec-0010}
=======

Geraniol induces a distinctive gene expression profile {#cam4864-sec-0011}
------------------------------------------------------

We have previously shown that geraniol specifically suppresses cell survival and growth in PC‐3 cells, compared to linalool [11](#cam4864-bib-0011){ref-type="ref"}. To better understand the mechanism of action of geraniol, we compared gene expression profiles using the microarray data (GSE45567) obtained from vehicle‐, linalool‐, and geraniol‐treated PC‐3 cells. Our scheme for computational analyses is described in Figure S1. Hierarchical clustering algorithm clustered the microarray samples with whole 11,877 genes into three distinct groups (Fig. [1](#cam4864-fig-0001){ref-type="fig"}). These results indicate that geraniol induces the distinctive changes in gene expression, compared to linalool.

![Geraniol alters a gene expression profile. Hierarchical clustering illustrates large‐scale differences in gene expression among vehicle‐, linalool‐, or geraniol‐treated PC‐3 cell samples.](CAM4-5-2899-g001){#cam4864-fig-0001}

We then selected 5000 genes of the high variance across the nine samples, and confirmed that they still represent the same hierarchical clustering as Figure [1](#cam4864-fig-0001){ref-type="fig"} (Fig. S2A). An optimal cluster size was estimated by clValid algorithm in various unsupervised clustering algorithms to assess cluster stability. clValid predicted that the cluster size 2 would be the most dependable by every clustering algorithm with the maximum Dunn index of 1.17 (Table S1). For validation, CLARA identified that vehicle‐ and linalool‐treated samples constructed one cluster and geraniol‐treated samples constituted another cluster by ED metric. However, internal validation by PCA and supervised classification by Random Forest showed that vehicle‐, linalool‐, and geraniol‐treated samples can be separated into independent clusters, supporting the hierarchical clustering analysis (Fig. S2B and Table S2). These findings reaffirm that geraniol induces a unique gene expression profile change.

Geraniol regulates cell cycle gene signatures {#cam4864-sec-0012}
---------------------------------------------

SAM analysis revealed that geraniol specifically affected the expression levels of 2527 genes in PC‐3 cells (Fig. [2](#cam4864-fig-0002){ref-type="fig"}A). Using these genes, we examined the effect of geraniol on GO biological process. GSEA identified 25 down‐regulated and 3 up‐regulated gene signatures with *q*‐value 0.2 (Table S3). Of the 28 gene signatures, 13 signatures were associated with cell cycle or proliferation and 8 cell cycle‐related signatures were placed on the top with small normalized enrichment score (NES) values (indicated by blue in Table S3). The network visualization of enriched GO terms also showed that the geraniol primarily down‐regulates cell cycle‐ or proliferation‐related gene signatures (Fig. [2](#cam4864-fig-0002){ref-type="fig"}B). To confirm these computational findings, we analyzed cell cycle profile. Geraniol increased G~2~/M phase, which is more evident in thymidine‐nocodazole block experiments (Fig. [2](#cam4864-fig-0002){ref-type="fig"}C). Geraniol prevented the cell relief from nocodazole block.

![Geraniol down‐regulates cell cycle gene signatures. (A) Geraniol specifically alters the expression levels of 2527 genes. (B) Network visualization of GO enrichment analysis. Blue nodes represent down‐regulated and red nodes represent up‐regulated GO‐terms in the geraniol cluster. Node color intensity, node size, and edge thickness are proportional to value of normalized enrichment score (NES), the number of genes in gene signature, and the number of overlapping genes between two connected nodes. (C) PC‐3 cells were synchronized by thymidine‐nocodazole blockage and then treated with 1 mM linalool or geraniol for 24 h prior to flow cytometric analysis. Cell fraction is expressed as the percentage of cells in each phase of the cell cycle. The data were expressed as the mean ± SEM (*n* = 3). \**P *\< 0.05, \*\*\**P *\< 0.005. V, vehicle; L, linalool, G, geraniol; GO, Gene Ontology.](CAM4-5-2899-g002){#cam4864-fig-0002}

E2F8 is identified as a master regulator in prostate cancer {#cam4864-sec-0013}
-----------------------------------------------------------

We found 79 leading edge subset (LES) genes (Table S4) overlapping across the 13 cell cycle‐related signatures and denoted them as geraniol‐specific cell cycle signatures for MRA. We then investigated the transcriptional regulatory mechanisms that determine the geraniol‐specific cell cycle signatures. ARACNe algorithm inferred a small consensus network of 161,446 interactions from the 462 human TF hub markers and the 5000 genes of high variance. From this transcriptional interactome, the MRA algorithm identified 40 TFs as master regulator (MR) candidates that down‐regulate geraniol‐specific cell cycle signatures. In addition, the MARINa algorithm inferred 224 TFs as MR candidates that differentiate the geraniol cluster from the vehicle one (Table S5): the 71 MRs out of 226 were negatively enriched and 153 MRs were positively enriched in the geraniol cluster.

We then found that 28 MRs are commonly found in both the MRA and the MARINa algorithms (Fig. [3](#cam4864-fig-0003){ref-type="fig"}A and Table [1](#cam4864-tbl-0001){ref-type="table-wrap"}). The gene expression levels of 28 MRs were markedly altered in the geraniol cluster (heatmap in Fig. [3](#cam4864-fig-0003){ref-type="fig"}B) and correlated with those of their target genes (red bars in Fig. [3](#cam4864-fig-0003){ref-type="fig"}B). Of the 28 MRs, E2F8 as a top inactivated MR in the geraniol cluster was identified to regulate 58 target genes in the geraniol‐specific cell cycle signature genes (Table S6 and Fig. S3). Out of the 58 target genes, 18 genes are involved in G~2~/M phase cell cycle process according to molecular signature database (indicated in bold in Table S6). Indeed, geraniol specifically reduced the expression of E2F8 at both mRNA and protein levels in PC‐3, compared to linalool (Figs. [3](#cam4864-fig-0003){ref-type="fig"}C and S6). We also obtained the comparable results from LNCaP prostate cancer cells (Fig. [3](#cam4864-fig-0003){ref-type="fig"}C). In addition, we identified that geraniol regulated the expression levels of other several master regulators (Fig. S4).

![E2F8 as a master regulator controls geraniol‐specific cell cycle signatures. (A) 28 master regulators (MRs) are overlapping between the 40 MRs found by master regulator analysis and 226 MRs predicted by MARINa. (B) The heatmap shows the differences in gene expression levels of the 28 MRs in each sample. The mode explains whether geraniol positively (+) or negatively (−) affects the expression of MRs. Bar graph shows the distribution of positively (red) or negatively (blue) correlated target genes of the MRs (Spearman\'s correlation between the expression levels of the MR and its targets). (C) PC‐3 or LNCaP cells were treated with 1 mM linalool or geraniol for 24 h prior to RT‐PCR (upper) or western blot analysis (lower). *β*‐actin or tubulin was used as an internal or a loading control, respectively.](CAM4-5-2899-g003){#cam4864-fig-0003}

###### 

List of 28 master regulators that control geraniol‐specific cell cycle signatures

  Gene ID   Gene symbol   Gene description                                     FET *P* ‐Value[a](#cam4864-note-0003){ref-type="fn"}   Markers in regulon[b](#cam4864-note-0004){ref-type="fn"}   Markers in intersection set[c](#cam4864-note-0005){ref-type="fn"}   Mode[d](#cam4864-note-0006){ref-type="fn"}   Odds Ratio[e](#cam4864-note-0007){ref-type="fn"}   NES[f](#cam4864-note-0008){ref-type="fn"}   absNES   Fold Change[g](#cam4864-note-0009){ref-type="fn"}   *q*‐value[g](#cam4864-note-0009){ref-type="fn"}
  --------- ------------- ---------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------- -------------------------------------------------- ------------------------------------------- -------- --------------------------------------------------- -------------------------------------------------
  79733     E2F8          E2F transcription factor 8                           3.31E‐43                                               478                                                        58                                                                  ---                                          15.00                                              −13.72                                      13.72    0.66                                                0.00
  4605      MYBL2         v‐myb myeloblastosis viral oncogene homolog‐like 2   9.02E‐30                                               539                                                        50                                                                  ---                                          15.77                                              −13.79                                      13.79    0.68                                                0.00
  2146      EZH2          Enhancer of zeste homolog 2 (Drosophila)             7.32E‐24                                               578                                                        46                                                                  ---                                          12.25                                              −14.68                                      14.68    0.73                                                0.00
  1063t     CENPF         Centromere protein F, 350/400 kDa (mitosin)          1.75E‐21                                               493                                                        41                                                                  ---                                          16.32                                              −12.51                                      12.51    0.56                                                0.00
  3148      HMGB2         High mobility group box 2                            3.34E‐20                                               501                                                        40                                                                  ---                                          8.74                                               −12.44                                      12.44    0.63                                                0.00
  3149t     HMGB3         High mobility group box 3                            6.28E‐24                                               400                                                        40                                                                  ---                                          16.41                                              −11.34                                      11.34    0.75                                                0.00
  8914      TIMELESS      Timeless homolog (Drosophila)                        1.04E‐21                                               457                                                        40                                                                  ---                                          10.64                                              −12.38                                      12.38    0.83                                                0.00
  865       CBFB          Core‐binding factor, beta subunit                    8.91E‐15                                               597                                                        37                                                                  ---                                          9.97                                               −13.25                                      13.25    0.85                                                0.01
  8607      RUVBL1        RuvB‐like 1 (*E. coli*)                              1.29E‐11                                               751                                                        37                                                                  ---                                          9.14                                               −13.41                                      13.41    0.73                                                0.00
  11137     PWP1          PWP1 homolog (*S. cerevisiae*)                       1.47E‐14                                               571                                                        36                                                                  ---                                          6.98                                               −12.81                                      12.81    0.90                                                0.24
  2305      FOXM1         Forkhead box M1                                      2.07E‐15                                               504                                                        35                                                                  ---                                          11.99                                              −13.21                                      13.21    0.69                                                0.00
  9232      PTTG1         Pituitary tumor‐transforming 1                       2.52E‐15                                               475                                                        34                                                                  ---                                          10.12                                              −12.19                                      12.19    0.54                                                0.00
  4602      MYB           v‐myb myeloblastosis viral oncogene homolog          4.96E‐14                                               524                                                        34                                                                  ---                                          11.80                                              −11.35                                      11.35    0.62                                                0.00
  7468      WHSC1         Wolf‐Hirschhorn syndrome candidate 1                 9.73E‐12                                               590                                                        33                                                                  ---                                          9.17                                               −13.29                                      13.29    0.77                                                0.00
  9735      KNTC1         Kinetochore associated 1                             2.44E‐16                                               354                                                        31                                                                  ---                                          10.77                                              −10.71                                      10.71    0.70                                                0.00
  10856     RUVBL2        RuvB‐like 2 (*E. coli*)                              4.11E‐12                                               502                                                        31                                                                  ---                                          8.55                                               −11.67                                      11.67    0.83                                                0.00
  4603      MYBL1         v‐myb myeloblastosis viral oncogene homolog‐like 1   4.01E‐14                                               336                                                        28                                                                  ---                                          11.84                                              −10.73                                      10.73    0.76                                                0.00
  2130      EWSR1         Ewing sarcoma breakpoint region 1                    5.32E‐13                                               372                                                        28                                                                  ---                                          12.31                                              −8.79                                       8.79     0.82                                                0.00
  5252      PHF1          PHD finger protein 1                                 1.46E‐10                                               468                                                        28                                                                  \+                                           7.60                                               11.45                                       11.45    1.16                                                0.02
  10849     CD3EAP        CD3e molecule, epsilon‐associated protein            3.76E‐11                                               378                                                        26                                                                  ---                                          17.60                                              −11.50                                      11.50    0.79                                                0.00
  221037    JMJD1C        Jumonji domain containing 1C                         1.08E‐08                                               453                                                        25                                                                  \+                                           19.28                                              9.36                                        9.36     1.32                                                0.00
  7020      TFAP2A        Transcription factor AP‐2 alpha                      4.85E‐10                                               359                                                        24                                                                  \+                                           5.16                                               6.01                                        6.01     1.23                                                0.00
  10042     HMGXB4        HMG box domain containing 4                          1.86E‐05                                               582                                                        23                                                                  ---                                          7.59                                               −10.37                                      10.37    0.76                                                0.00
  5036      PA2G4         Proliferation‐associated 2G4, 38 kDa                 2.06E‐08                                               364                                                        22                                                                  ---                                          14.26                                              −11.18                                      11.18    0.82                                                0.00
  9569      GTF2IRD1      GTF2I repeat domain containing 1                     1.07E‐07                                               331                                                        20                                                                  \+                                           6.67                                               7.26                                        7.26     1.19                                                0.01
  7027      TFDP1         Transcription factor Dp‐1                            2.12E‐06                                               398                                                        20                                                                  ---                                          15.56                                              −11.73                                      11.73    0.70                                                0.00
  86        ACTL6A        Actin‐like 6A                                        1.55E‐06                                               287                                                        17                                                                  ---                                          7.17                                               −3.26                                       3.26     0.76                                                0.00
  25909     AHCTF1        AT hook containing transcription factor 1            1.96E‐05                                               346                                                        17                                                                  ---                                          7.02                                               −8.44                                       8.44     0.83                                                0.01

The 28 MRs were sorted by largest to smallest by Markers in intersection set in descendent order. Odds ratio, NES, fold change and *q*‐value were rounded off to two decimal places.

FET *P ‐*value, the *P ‐*value from Fisher\'s exact test. It shows how much significantly the marker (gene) belongs to the signature set and the regulon of the master regulator (MR).

Markers in regulon, the number of markers (genes) found to be first neighbors of the master regulator in the loaded network.

Makers in intersection set, the number of markers found in the intersection of the signature and the regulon of the candidate MR.

Mode, plus mode means that the MR is positively correlated with up‐regulated regulons in geraniol cluster, and minus mode means that the MR is positively correlated with down‐regulated genes in geraniol cluster.

Odd Ratio, odds of a regulon gene being in the GSEA leading edge set/odds of a regulon gene being in the GSEA trailing edge set.

NES, GSEA normalized enrichment score for the regulon of the TF.

Fold change and *q‐value* were calculated from SAM analysis.
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E2F8 knockdown induces G~2~/M arrest {#cam4864-sec-0014}
------------------------------------

To assess the role of E2F8 in geraniol‐induced phenotypic changes, rescue experiments were performed. We found that E2F8 overexpression reversed geraniol‐induced G~2~/M arrest (Fig. [4](#cam4864-fig-0004){ref-type="fig"}). We then knocked down the level of E2F8 using siRNA against E2F8 (siE2F8). We first tested three different siE2F8s in PC‐3 cells. All tested siE2F8s suppressed cell growth and induced G~2~/M arrest (Fig. S5), excluding the off‐target effect of siRNAs. Because siE2F8‐1 was more effective than other siE2F8s, we chose siE2F8‐1 in following studies.

![The effect of E2F8 overexpression on geraniol‐induced G~2~/M arrest. PC‐3 cells were transfected with human E2F8 in pcDNA3 and then incubated with 1 mmol/L geraniol for 24 h prior to flow cytometric analysis (upper) or western blotting (lower). \**P *\< 0.05, \*\*\**P *\< 0.005.](CAM4-5-2899-g004){#cam4864-fig-0004}

We examined the effect of siE2F8‐1 on cell cycle profile in PC‐3 and LNCaP cells. MTT assays showed that E2F8 knockdown suppressed cell growth (Fig. [5](#cam4864-fig-0005){ref-type="fig"}A and D). In addition, siE2F8‐1 markedly increased cell populations in the G~2~/M phase (Fig. [5](#cam4864-fig-0005){ref-type="fig"}B and E) and induced the changes in the levels of cyclin A, cyclin B1, phospho‐CDK2, and phospho‐histone H3, which are G~2~/M transition regulatory proteins (Fig. [5](#cam4864-fig-0005){ref-type="fig"}C and F). These results indicate that E2F8 knockdown substantially reproduces geraniol‐induced G~2~/M arrest phenotype. In addition, our findings suggest that E2F8 plays a crucial role in the regulation of G~2~/M cell cycle in prostate cancer cells.

![E2F8 knockdown induces G~2~/M arrest and apoptosis. PC‐3 (A--C) or LNCaP (D--F) cells were transfected with 100 nmol/L siE2F8 for the indicated times prior to MTT assay (A and D), cell cycle analysis (B and E), and western blot analysis (C and F). Cell growth was expressed as a relative value compared to that of siGFP as a control which was set to 100%. The data were expressed as the mean ± SEM (*n* = 3). \**P *\< 0.05, \*\**P *\< 0.01, \*\*\**P *\< 0.005.](CAM4-5-2899-g005){#cam4864-fig-0005}

Clinical relevance of E2F8 in prostate cancer {#cam4864-sec-0015}
---------------------------------------------

To address the clinical relevance of our findings, we examined the expression levels of E2F8 using microarray datasets of prostate cancer patients (GSE21034 and GSE3325) [28](#cam4864-bib-0028){ref-type="ref"}, [29](#cam4864-bib-0029){ref-type="ref"}. The averages of normalized E2F8 expression levels were calculated from benign, primary, and metastatic tumor samples; its relative expression levels were ‐0.054, −0.025, and 0.146, respectively (ANOVA test, *P *= 3.44e^−12^; Fig. [6](#cam4864-fig-0006){ref-type="fig"}A). This result suggests that the increased expression of E2F8 is associated with prostate cancer metastasis. To assess the effect of E2F8 on clinical outcome, we compared overall survival in the prostate cancer patients with low‐ and high‐expression of E2F8. Kaplan--Meier analysis indicated that the patients with high expression of E2F8 had significantly worse overall survival than those with low expression (HR = 2.912 and log‐rank test *P *= 0.048) (Fig. [6](#cam4864-fig-0006){ref-type="fig"}B).

![Clinical relevance of E2F8 in prostate cancer patients. (A) The expression levels of E2F8 in prostate cancer patient samples (GSE21034 and GSE3325) were represented in the box‐plot. The *x*‐axis indicates three different stages of prostate cancer and *y*‐axis represents the normalized expression level of E2F8. (B) Survival curve for prostate cancer patients (ICGC dataset) based on the expression levels of E2F8. HR, hazard ratio (95% confidence interval).](CAM4-5-2899-g006){#cam4864-fig-0006}

Discussion {#cam4864-sec-0016}
==========

In this study, we described four main findings: (1) geraniol specifically induces the changes in cell cycle gene signatures; (2) geraniol reduces the expression levels of the transcription factor E2F8; (3) E2F8 controls G~2~/M cell cycle progression; and (4) E2F8 is up‐regulated in metastatic prostate cancer and associated with worse survival in prostate cancer patients.

We have found that geraniol can be a useful chemical probe for dissecting the complicated phenotypes of prostate cancer and identifying therapeutic target molecules [10](#cam4864-bib-0010){ref-type="ref"}, [11](#cam4864-bib-0011){ref-type="ref"}. In this study, we performed clustering analysis, pathway‐based approach, and master regulator analysis using the microarray data and identified E2F8 as a target TF of geraniol. E2F8 is a member of atypical E2F family that regulates cell survival and embryonic development [35](#cam4864-bib-0035){ref-type="ref"}. However, it is unclear whether E2F8 functions as a transcriptional repressor or activator [36](#cam4864-bib-0036){ref-type="ref"}, [37](#cam4864-bib-0037){ref-type="ref"}. Emerging evidence suggests that E2F8 contributes to the oncogenic potentials of several types of cancer, such as hepatic or lung cancer [30](#cam4864-bib-0030){ref-type="ref"}, [31](#cam4864-bib-0031){ref-type="ref"}. Our study reveals that E2F8 exerts pro‐oncogenic activity in prostate cancer via G~2~/M cell cycle regulation.

Our results indicate that E2F8 is required for the growth of prostate cancer cells and is aberrantly expressed in metastatic prostate cancer. In addition, we demonstrate that the overexpression of E2F8 has clinically relevant prognostic significance in prostate cancer. Therefore, these findings suggest that E2F8 is a novel targetable molecule for treatment of metastatic prostate cancer or CRPC patients. Our results provide a basis for future investigations aiming at elucidating the molecular mechanisms underlying the expression or activity of E2F8 in prostate cancer, which assists to understand the role of E2F8 in CRPC biology and to develop novel cell cycle‐targeted therapeutic strategies.
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**Figure S1**. Schematic diagram for the computational approaches.
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**Figure S2**. Gene expression profiles and PCA plot.
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**Figure S3.** Gene expression of E2F8 target genes across three clusters.
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**Figure S4.** The expression levels of master regulators.
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**Figure S5.** The effect of siRNAs against E2F8 on cell growth and cell cycle.
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**Figure S6.** Full scan images of used in this study.
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**Table S1.** Summary of Dunn index in the different cluster size by clValid analysis.

**Table S2.** Classification of monoterpene‐treated PC‐3 cell microarray samples by Random Forest.

**Table S3**. List of 28 gene signatures of Gene Ontology Biological Process in the geraniol cluster.

**Table S4.** List of 79 LES genes that cover all of the LES genes from cell cycle and proliferation gene signatures.

**Table S5**. The result of MARINa analysis: 224 TFs that were activated or inactive in the geraniol cluster.

**Table S6**. List of 58 target genes of E2F8.
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